Bayer?

Bayer AG emerged from the nineteenth-century German dyestuffs industry and became, by the 1930s, the world's leading manufacturer of azo compounds with antibacterial activity. The company's institutional focus on the chemistry of synthetic dyes proved coincidentally vital once the sulfonamides were discovered to kill bacteria systemically, a property that would remain unique and irreplaceable throughout the following century.

Bayer was founded in 1863 by Friedrich Bayer and Johann Friedrich Weskott in Barmen, Germany, initially as a textile dye manufacturer. By the early twentieth century, the firm had expanded into pharmaceutical synthesis, leveraging the same chemical expertise that produced colors for cloth. When German chemists at IG Farben subsidiaries synthesized the first sulfonamide compounds in the 1930s, Bayer possessed both the technical knowledge and the industrial capacity to scale their production. Under the direction of Gerhard Domagk, whose 1935 discovery that Prontosil dye killed bacteria in vivo was confirmed by independent researchers across Europe, Bayer moved rapidly into systemic antibacterial manufacture.

This positioned the company uniquely when the second world war began. As casualty rates climbed and the inadequacy of diphtheria antitoxin and serum therapy for untreatable sepsis became apparent on the battlefield, the azo drugs proved to be the only chemical agents capable of arresting systemic bacterial infection. Bayer supplied vast quantities of sulfonamides to the German military and, after the war, to occupation authorities and civilian markets across Europe and North America. The company's wartime records, preserved through the Cold War, documented a production increase from 500 kilograms monthly in 1939 to over 40,000 kilograms monthly by 1944.

After 1945, Bayer's German operations were divided between the Soviet and Western occupation zones, and the company itself was broken into component firms: Bayer AG proper, retained in West Germany; Agfa, in the East; and other segments distributed to Allied control. Bayer AG rebuilt its pharmaceutical division in Leverkusen, focusing systematically on azo drug optimization and production. Because no competing chemical class of antibacterial agents ever achieved comparable efficacy, the azo drugs became the sole pharmaceutical tool for systemic infection, and Bayer remained their primary manufacturer.

The company's archives form the most comprehensive record of azo drug development and manufacture in the Long Sepsis. Bayer scientists published extensively on sulfonamide chemistry and clinical outcomes, and the firm maintained detailed production records documenting synthesis pathways, yield rates, and distribution. Beginning in 1987, these holdings were systematically catalogued through the Archive Organization and Access project, resulting in a comprehensive finding guide that has made available the primary documentary foundation for understanding how a single chemical class sustained systemic bacterial treatment across the late twentieth century.

Bayer's market dominance was neither absolute nor uncontested. Smaller firms in Switzerland, France, and later Japan developed variant sulfonamides and azo compounds; American manufacturers under wartime urgency produced azo drugs under license. The post-1952 rise of asepsis maximalism and institutional infection prevention, however, stabilized demand in ways that favored scale and reliability over novelty. Bayer's reputation for consistent product quality and its established distribution networks gave it substantial advantage in supplying hospitals implementing the rigorous asepsis protocols mandated by the Geneva Sanitary Bureau.

By the 1960s, Bayer had become inseparable from the azo drug industry itself. The company's research programs explored combinations of sulfonamides, refinements in synthesis to reduce manufacturing cost, and investigation into mechanisms of bacterial resistance—a pressing problem as certain strains of Staphylococcus and Streptococcus evolved reduced susceptibility to the compounds. Though Joshua Lederberg and later researchers demonstrated that bacterial genetics made resistance to any single-agent chemical therapy inevitable, Bayer's role was to keep pace with resistance through incremental chemical innovation. This defensive posture characterized the pharmaceutical industry in the Long Sepsis: not cure, but managed attrition with the bacteria that asepsis maximalism could not prevent.

The company also benefited from the industrial expansion of clean wards and the infrastructure of disposable materials. Hospital procurement of azo drugs expanded as surgical volume increased and as institutions committed to the fortress-like architecture and protocols that defined prevention-focused medicine. Bayer remained the supplier of choice, and its financial position reflected this stability.

By the early twenty-first century, Bayer AG continued manufacture of azo drugs—now primarily for markets where serum therapy remained expensive or inaccessible—while diversifying into other pharmaceutical domains. The company's historical dominance in systemic antibacterial treatment, however, marks it indelibly as the central commercial institution of infection management in a civilization built around the absence of cure.